Clinical Observation About Atorvastatin Therapy Of Patients With ACS Undergoing PCI Emergency

Objective: Current clinical application of more effective acute coronarysyndrome (ACS) is a common serious harm to human health, symptoms of thedisease or disability, death rate, percutaneous coronary intervention(percutaneous coronary intervention, PCI) is means. PCI at the same timeimmediately improve coronary occlusion or stenosis lesions, can cause intimaltear exfoliation, plaque rupture, debris falling, micro-thrombosis, inevitablyresulting in endothelial cell structure and function damage. This study aimedto investigate the acute coronary syndrome patients undergoing emergencyPCI interventional treatment of postoperative lipid lowering with atorvastatinto strengthen the impact of sequential therapy.Methods: February2012to December2013in our hospital Cardiologyacute coronary syndrome undergoing emergency PCI,28patients wererandomly divided into groups that intraoperative application before the trial ofatorvastatin calcium tablets80mg Dayton clothing, after40mg/d, the controlgroup that preoperative atorvastatin calcium tablets20mg Dayton clothing,after20mg/d. All patients underwent emergency after PCI, givensymptomatic conventional treatment, including anti-platelet therapy, drugtherapy nitrates, β-blockers and ACEI therapy. Follow-up three months aftertreatment, changes in liver function observed lipids alter serum inflammatoryfactors change the situation, adverse drug reactions and adverse cardiac events.Application of SPSS17.0statistical software for processing and analysis oftest results. The resulting test data count data for the experimental group andthe control group using the chi-square test, measurement data for the two testgroups were presented as mean±standard deviation, t-test between the twogroups. P <0.05was considered statistically significant. Results: The28patients in the deletion0cases, shedding0cases,28patients entered the intention to treat (rT) analysis, consistent with theprogram (PP) analysis of28cases, baseline characteristics of the two groupswere comparable (P>0.05); medication after two TC and LDL-C groupshowed a clear downward trend, medication a month when two TC, LDL-Cwas no significant difference;23months when the drug test group TC, LDL-Cwas significantly lower than the control group (P <0.05); groups TG, HDL-Cwas no significant difference (P>0.05); groups (3days,1and3months) GPT,CK abnormalities were not significantly different (P>0.05). Two drugs (3days,1and3months) after two hs-CRP, MMP-9were decreased, medication(3days,1and3months) when the test group hs-CRP, MMP-9wassignificantly lower than the control group (P <0.05). Within three monthsadverse cardiac events were observed, the test group the incidence of adversecardiac events was significantly lower than the control group (P <0.05).Conclusion: Patients with acute coronary syndrome undergoingemergency PCI intervention, atorvastatin enhanced security higher sequentialtherapy can effectively reduce TC, LDL-C levels, and inhibit hs-CRP, MMP-9expression and reduce plaque and vascular damage, reduce the incidence ofadverse cardiac events, there is a high clinical value.